Baseline characteristics of patients with and without pre-existing ILD
| All patients (n=163) | With pre-existing ILD (n=58) | Without pre-existing ILD (n=105) | p Value | |
|---|---|---|---|---|
| Age—years | 60.9±11.6 | 66.1±9.1 | 57.8±12.6 | <0.001 |
| Gender—male/female—N | 45/118 | 26/32 | 19/86 | <0.001 |
| Duration from diagnosis—years | 10.2±11.0 | 11.2±9.7 | 9.9±10.5 | 0.240 |
| State of RA | ||||
| Stage | 2.4±1.1 | 2.3±1.0 | 2.4±1.1 | 0.508 |
| Class | 2.1±0.5 | 2.3±0.5 | 2.0±0.4 | <0.01 |
| Biological therapy—N (%) | ||||
| TNF inhibitors | 102 (63) | 46 (79) | 56 (53) | <0.01 |
| Adalimumab | 6 (4) | 2 (3) | 4 (4) | 1.0 |
| Etanercept | 63 (39) | 36 (62) | 27 (26) | <0.001 |
| Infliximab | 33 (20) | 8 (14) | 25 (24) | 0.156 |
| Non-TNF inhibitors | 51 (37) | 12 (21) | 49 (47) | <0.01 |
| Anti-IL-6 receptor antibody | ||||
| Tocilizumab | 36 (22) | 9 (16) | 27 (26) | 0.168 |
| CTLA4-Ig | ||||
| Abatacept | 25 (15) | 3 (5) | 22 (21) | <0.01 |
| ILD grade—N (%) | ||||
| 1 | 30 (52) | |||
| 2 | 22 (38) | |||
| 3 | 6 (10) | |||
| ILD events—N (%) | 17 (10) | 14 (24) | 3 (3) | <0.001 |
| Mild | 10 (6) | 10 (17) | – | |
| Moderate | 6 (4) | 3 (5) | 3 (3) | 0.612 |
| Severe | 1 (1) | 1 (2) | 0 | 0.349 |
Plus-minus values are means±SD.
CTLA4-Ig, cytotoxic T-lymphocyte antigen 4-immunoglobulin; ILD, interstitial lung disease; RA, rheumatoid arthritis; TNF, tumour necrosis factor.